文献速递脑血管病头痛与眩晕

曲普坦类药物起始者卒中与心肌梗死风险

Risk of Stroke and Myocardial Infarction Among Initiators of Triptans.
PubMed 文献 · JAMA Neurol · 2024-01-01

基于丹麦全国登记数据,采用病例交叉设计比较首次使用曲普坦前2周与四个2周参照期的缺血事件风险。结果显示曲普坦起始与缺血性卒中(OR 3.2,95%CI 1.3-8.1)和心肌梗死(OR 3.3,95%CI 1.0-10.9)风险升高相关,但绝对风险极低。

要点

  • 曲普坦起始与缺血性卒中风险升高相关(OR 3.2,95%CI 1.3-8.1)。
  • 曲普坦起始与心肌梗死风险升高相关(OR 3.3,95%CI 1.0-10.9)。
  • 低心血管背景风险者起始曲普坦后缺血事件绝对风险很低。

核心结论

  • 病例交叉研究提示曲普坦起始与缺血性卒中和心肌梗死风险升高相关,但个体绝对风险很低。

研究设计与样本

  • 基于丹麦全国登记数据,纳入1995年1月至2022年8月首次兑换曲普坦处方且发生预设缺血结局的个体,采用病例交叉设计比较事件前2周与四个2周参照期的曲普坦暴露。
  • 共识别429,612名首次兑换曲普坦处方者,中位年龄38岁(IQR 28-48),女性325,687人(75.8%)。

主要发现

  • 首次曲普坦处方后发生心肌梗死者11例(0.003%),OR 3.3(95%CI 1.0-10.9)。
  • 发生缺血性卒中者18例(0.004%),OR 3.2(95%CI 1.3-8.1)。
  • 发生缺血性/非特异性卒中者35例(0.008%),OR 3.0(95%CI 1.5-5.9)。
  • 病例中位年龄约60岁,具有高风险心血管特征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Triptans are contraindicated in patients with ischemic heart disease or previous myocardial infarction, and caution is advised when prescribing these drugs to patients with vascular risk factors. However, controlled observational studies have either shown no association or an apparent lower risk, possibly owing to a channeling of triptans to individuals at low risk of cardiovascular outcomes, and it remains unclear whether avoiding triptan treatment for these patients is meaningful. OBJECTIVE: To establish whether an association between triptans and ischemic events could be demonstrated using a self-controlled design because this type of design is robust to the previously mentioned type of confounding. DESIGN, SETTING, AND PARTICIPANTS: All people in nationwide Danish registries who were initiating triptans and all the ischemic events that they experienced were identified. A case-crossover design was used to estimate odds ratios (OR) for associations between first-ever triptan use and ischemic outcomes, comparing triptan exposure in the 2-week period up to the event with four 2-week reference periods. Data were obtained for the period January 1995 to August 2022. Included from the population of Denmark were individuals redeeming a prescription for any triptan and experiencing at least 1 of 3 predefined ischemic outcomes. No one was excluded. EXPOSURE: Initiation of any triptan. MAIN OUTCOMES AND MEASURES: Acute myocardial infarction, ischemic stroke, or nonspecified stroke. RESULTS: Identified were a total of 429 612 individuals (median [IQR] age, 38 [28-48] years; 325 687 female [75.8%]) who redeemed a first prescription for a triptan in the study period. Of these patients, 11 (0.003%) had a myocardial infarction with the first triptan prescription in either a focal or referent window (odds ratio [OR], 3.3; 95% CI, 1.0-10.9), 18 (0.004%) had ischemic stroke (OR, 3.2; 95% CI, 1.3-8.1), and 35 (0.008%) had ischemic/nonspecified stroke (OR, 3.0; 95% CI, 1.5-5.9). Case patients had a median age of approximately 60 years and had a high-risk cardiovascular profile. CONCLUSIONS AND RELEVANCE: Results of this case-crossover study suggest that triptan initiation was associated with higher risk of ischemic stroke and myocardial infarction. For the individual patient with low background cardiovascular risk, the risk of an ischemic event after triptan initiation was very low.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Petersen CL, Hougaard A, Gaist D, et al. Risk of Stroke and Myocardial Infarction Among Initiators of Triptans. JAMA Neurol. 2024. PMID: 38315477. doi:10.1001/jamaneurol.2023.5549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。